<DOC>
	<DOCNO>NCT01380223</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacodynamics omecamtiv mecarbil infusion healthy male volunteer .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study Omecamtiv Mecarbil Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Subject male 2 . Subject age 18 50 year inclusive . 3 . Subject give sign informed consent . 4 . Subject 's Body Mass Index ( BMI ) 18 30 kg/m2 inclusive . 5 . Subject weigh less 100 kg . 6 . Subject consider good health opinion investigator , determine : 1 . A prestudy physical examination clinically significant abnormality . 2 . Vital sign within normal range ( supine 3 minute rest heart rate : 40 80 bpm ; systolic BP : 100 140 mmHg ; diastolic BP : 5090 mmHg ; respiration rate : 8 18 breath per minute ; oxygen saturation : 96100 % ) 3 . An ECG clinically significant abnormality . 7 . Subject 's prestudy clinical laboratory finding within normal range outside normal range deem clinically significant opinion investigator . 8 . Cardiac troponin I less upper limit laboratory reference range . 9 . A screening echocardiogram demonstrate normal cardiac function , ejection fraction 40 % 70 % significant valvular regurgitation ( grade 1 ) and/or stenosis image deem good quality sonographer . 1 . Subject clinically significant illness four week screen . 2 . Use prescribed mediation 3 week prior dose overthecounter preparation ( include vitamin supplement herbal remedy ) 7 day prior dose , except paracetamol allow 48 hour prior dose . 3 . Subject significant history drug/solvent abuse positive drug abuse test screening . 4 . Subject history alcohol abuse currently drink excess 28 unit per week . 5 . Subject smoke 5 cigarette ( equivalent ) per day . 6 . Subject willing refrain caffeine/xanthine containing product 48 hour prior screen medical admission Day 1 post study medical . 7 . Subject opinion investigator suitable participate study . 8 . Subject participate clinical study investigational drug/device within three month prior first day dose . 9 . Subject positive result HIV screen , Hepatitis B screen Hepatitis C screen . 10 . Subject serious adverse reaction significant hypersensitivity drug . 11 . Subject donate 500 ml blood within month prior screen . 12 . Subject history cardiovascular disease family history premature cardiovascular disease death .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>